SR123781A, a synthetic heparin mimetic

Thrombosis and Haemostasis

Volumn 85, Issue 5, 2001, Pages 852-860

  Herbert, J M ^a   Herault J P ^a   Bernat, A ^a   Savi, P ^a   Schaeffer, P ^a   Driguez, P A ^a   Duchaussoy, Ph ^a   Petitou, M ^a  

^a SANOFI   (France)

Author keywords

Factor Xa; Heparin mimetic; SR123781A; Thrombin; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN COFACTOR II; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; SR 123781A; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOVENOUS SHUNT; ARTICLE; BINDING AFFINITY; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR DEFICIENCY; CATALYST; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INHIBITION; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; RAT; RECEPTOR INTRINSIC ACTIVITY; STANDARD; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 0035016364     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615759     Document Type: Article

References (43)

1. The structure of heparin oligosaccharide fragments with anti-factor Xa activity containing the minimal antithrombin III-binding sequence
2. The effect of the synthetic pentasaccharide SR 90107/Org31540 on thrombin generation ex vivo is uniquely due to AT-III-mediated neutralization of factor Xa
3. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
4. Structure and biological activity of heparin
5. The clot thickens: Clues provided by thrombin structure
6. Regulation of thrombin activity by antithrombin and heparin
7. Heparin-induced thrombocytopenia: Towards consensus
8. The unique antithrombin binding domain of heparin: A lead to new synthetic antithrombotics
9. The action of a synthetic pentasaccharide on thrombin generation in whole plasma
10. Comparison of two experimental thrombosis models in rats: Effect of four glycosaminoglycans
11. Pharmacological profile of the chemically synthetized antithrombin III binding fragment of heparin (pentasaccharide) in rats
12. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model
13. Anti-thrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges
14. Importance of a 3-O-sulphate group in a heparin pentasaccharide for antithrombotic activity
15. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates
16. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/Org 31540) with high affinity for antithrombin III in man
17. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent
18. Synthesis of thrombin-inhibiting heparin mimetics without side effects
19. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and non-specific binding models
20. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity
21. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes
22. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide
23. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III
24. The aggregation of blood platelets
25. Specific binding of the chemokine platelet factor 4 to heparan sulfate
26. A diagnostic test for heparin-thrombocytopenia
27. Effect of KC-6141, an anti-aggregating compound, on experimental thrombosis in rats
28. Experimental model of venous thrombosis in rats and effects of some agents
29. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin - Prediction of the in vivo residence times
30. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins
31. Does low molecular weight heparin cause less bleeding?
32. Advances in selective chemical syntheses of complex oligosaccharides
33. Biochemical and pharmacological properties of Sanorg32701. Comparison with the "synthetic pentasaccharide" (SR90107/Org31540) and standard heparin
34. Biochemical and pharmacological properties of Sanorg34006, a potent and long-acting synthetic pentasaccharide
35. Insight into the mechanism of action of heparin cofactor II
36. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
37. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY 216
38. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats
39. Antithrombotic effects of recombinant hirudin in different animal models
40. Recombinant desulphatohirudin (CGP39393). Anticoagulant and antithrombotic properties in vivo
41. Pharmacological assessment of antithrombotic activity of the peptide inhibitor, D-methyl-phenylalanyl-prolyl-arginyl (GYKI-14766), in a canine model of coronary artery thrombosis